Hikma has set out its expectations for a “gradual ramp-up” of the 503B sterile injectable compounding business that it has launched in the US this month, with CEO Siggi Olafsson explaining in detail the strategic rationale for the new business.
Hikma’s new compounding business, Hikma 503B, is set to address an increasing need in the US market for compounded sterile injectable medications while at the same time taking advantage of the company’s existing expertise in injectables to enter a market worth more than $2bn, according to CEO Siggi Olafsson.
Launching the new outsourced sterile compounding business in mid-January, Hikma insisted that it would “build on the company’s expertise and...
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
